Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207624 | 1.00 | RIPK1 (0.51) | RIPK1HCRTR2HSD17B10GPR119NPC1 | |
| SCHEMBL24332603 | 0.92 | GPR119 (0.46) | RIPK1HCRTR2GPR119KDM1ANR1H2 | |
| SCHEMBL29573647 | 0.92 | GPR119 (0.46) | RIPK1HCRTR2GPR119KDM1ANR1H2 | |
| SCHEMBL26303517 | 0.92 | GPR119 (0.46) | RIPK1HCRTR2GPR119KDM1ANR1H2 | |
| SCHEMBL28379319 | 0.88 | MEN1 (0.43) | RIPK1HSD17B10NPC1UCHL1MEN1 | |
| SCHEMBL5784217 | 0.86 | RIPK1 (0.52) | RIPK1HCRTR2HSD17B10GPR119NPC1 | |
| SCHEMBL9025059 | 0.86 | RIPK1 (0.52) | RIPK1HCRTR2HSD17B10GPR119NPC1 | |
| SCHEMBL9023721 | 0.86 | RIPK1 (0.52) | RIPK1HCRTR2HSD17B10GPR119NPC1 | |
| SCHEMBL8125588 | 0.86 | RIPK1 (0.52) | RIPK1HCRTR2HSD17B10GPR119NPC1 | |
| SCHEMBL9024840 | 0.86 | RIPK1 (0.52) | RIPK1HCRTR2HSD17B10GPR119NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545525-B1 | RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-11-10 | — | — | EP | disclosed |
| EP-1119356-B1 | RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-1545525-A4 | RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7354935-B2 | Radiolabeled neurokinin-1 receptor antagonists | MERCK & CO. INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354935-B2 | Radiolabeled neurokinin-1 receptor antagonists | MERCK & CO. INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1119356-A4 | RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20050214204-A1 | Radiolabeled neurokinin-1 receptor antagonists | MERCK SHARP & DOHME CORP. | 2005-09-29 | — | — | US | disclosed |
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | PFIZER INC. (US) | 2005-08-04 | — | — | US | disclosed |
| EP-1545525-A2 | RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-0942733-B1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS | MERCK SHARP & DOHME (GB) | 2005-04-27 | — | — | EP | disclosed |
| US-5977104-A | Use of NK-1 receptor antagonists for treating bipolar disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-11-02 | — | — | US | disclosed |
| US-5972930-A | TREATING GASTROINTESTINAL DISORDER, A CENTRAL NERVOUS SYSTEM DISORDER, AN INFLAMMATORY DISEASE, EMESIS, URINARY INCONTINENCE, PAIN, MIGRAINE, SUNBURN, ANGIOGENESIS, DISEASES CAUSED BY HELICOBACTER PYLORI | PFIZER, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5952315-A | TREATING PHYSIOLOGICAL DISORDERS, DISORDERS OF THE CENTRAL NERVOUS SYSTEM SUCH AS ANXIETY, DEPRESSION AND PSYCHOSIS WITH AN ANTIDEPRESSANT | MERCK SHARP & DOHME LTD. (GB) | 1999-09-14 | — | — | US | disclosed |
| US-5929054-A | Use of NK-1 receptor antagonists for treating sexual dysfunctions | MERCK SHARP (GB) | 1999-07-27 | — | — | US | disclosed |
| US-5925627-A | Use of NK-1 receptor antagonists for treating movement disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-07-20 | — | — | US | disclosed |
| US-5919781-A | Use of NK-1 receptor antogonists for treating substance use disorders | MERCK SHARP & DOHME LTD. (GB) | 1999-07-06 | — | — | US | disclosed |
| WO-1999025714-A1 | PIPERIDINYLAMINOMETHYL TRIFLUOROMETHYL CYCLIC ETHER COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-05-27 | — | — | WO | disclosed |
| US-5789423-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; GASTROINTESTINAL AND CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1998-08-04 | — | — | US | disclosed |
| EP-0824100-A1 | Piperidinylamino tricyclic compouds as substance P antagonists | PFIZER INC. (US) | 1998-02-18 | — | — | EP | disclosed |
| EP-0780375-A1 | 3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists | PFIZER INC. (US) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050214204-A1 | Radiolabeled neurokinin-1 receptor antagonists | TACR1, TACR2, NTSR1 | RIPK1 2602/4885HCRTR2 72/4885HSD17B10 4346/4885 |
| US-20050171354-A1 | Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists | HRH2, TACR1, HRH4 | RIPK1 3890/4885HCRTR2 180/4885HSD17B10 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.